Irbesartan and Hydrochlorothiazide
Irbesartan and Hydrochlorothiazide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Irbesartan and Hydrochlorothiazide; Generic name: IRBESARTAN AND HYDROCHLOROTHIAZIDE; Drug class: Angiotensin 2 Receptor Blocker [EPC].
| Brand name | Irbesartan and Hydrochlorothiazide |
|---|---|
| Generic name | IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Drug class | Angiotensin 2 Receptor Blocker [EPC] |
| Manufacturer | Macleods Pharmaceuticals Limited |
| Used for | 1 INDICATIONS AND USAGE Irbesartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. Irbesartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy. Irbesartan and hydrochlorothiazide tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strok |
| Dosage | 2 DOSAGE AND ADMINISTRATION General Considerations • Maximum effects within 2 to 4 weeks after dose change. ( 2.1 ) • Renal impairment: Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). ( 2.1 , 5.8 ) Hypertension • Initiate with 150/12.5 mg. Titrate to 300/12.5 mg then 300/25 mg if needed. ( 2.2 ) • Replacement therapy: May be substituted for titrated components. ( 2.3 ) 2.1 General Considerations The side effects of irbesartan are generally rare and ap |
| Warnings | WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue irbesartan and hydrochlorothiazide tablets as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning . • When pregnancy |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1898f438-4571-4aab-ae06-9bf1aabf0486 |